These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 8145429)

  • 41. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Comparative economic data regarding lipid-lowering drugs.
    Schwartz JS
    Am Heart J; 1999 May; 137(5):S97-104. PubMed ID: 10220608
    [No Abstract]   [Full Text] [Related]  

  • 42. Lipids, blood pressure and kidney update 2014.
    Banach M; Aronow WS; Serban C; Sahabkar A; Rysz J; Voroneanu L; Covic A
    Pharmacol Res; 2015; 95-96():111-25. PubMed ID: 25819754
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The nicotinic acid receptor GPR109A (HM74A or PUMA-G) as a new therapeutic target.
    Offermanns S
    Trends Pharmacol Sci; 2006 Jul; 27(7):384-90. PubMed ID: 16766048
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparative effects of lovastatin and niacin in primary hypercholesterolemia. A prospective trial.
    Illingworth DR; Stein EA; Mitchel YB; Dujovne CA; Frost PH; Knopp RH; Tun P; Zupkis RV; Greguski RA
    Arch Intern Med; 1994 Jul; 154(14):1586-95. PubMed ID: 8031206
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Niacin fails to reduce vascular events in large randomised trial.
    McCarthy M
    BMJ; 2014 Jul; 349():g4774. PubMed ID: 25055803
    [No Abstract]   [Full Text] [Related]  

  • 46. [Current approaches to treatment of hypercholesterolemia].
    Preobrazhenskii VN; Matveev AA
    Klin Med (Mosk); 1996; 74(9):61-2. PubMed ID: 9121095
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Niacin, an old drug with new perspectives for the management of dyslipidaemia.
    Benhalima K; Muls E
    Acta Clin Belg; 2010; 65(1):23-8. PubMed ID: 20373594
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Niacin--a case study for the role of event-driven versus surrogate endpoint trials.
    Blaha MJ; Michos ED
    Heart; 2013 Nov; 99(22):1631-2. PubMed ID: 24041650
    [No Abstract]   [Full Text] [Related]  

  • 49. Clinical inquiries. Should liver enzymes be checked in a patient taking niacin?
    Rizakallah GS; Mertens MK; Brown ML; Sanner L
    J Fam Pract; 2005 Mar; 54(3):265-8. PubMed ID: 15755381
    [No Abstract]   [Full Text] [Related]  

  • 50. Niacin in HIV-infected individuals with hyperlipidemia receiving potent antiretroviral therapy.
    Gerber MT; Mondy KE; Yarasheski KE; Drechsler H; Claxton S; Stoneman J; DeMarco D; Powderly WG; Tebas P
    Clin Infect Dis; 2004 Aug; 39(3):419-25. PubMed ID: 15307011
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Hypophosphatemic effect of niacin in patients without renal failure: a randomized trial.
    Maccubbin D; Tipping D; Kuznetsova O; Hanlon WA; Bostom AG
    Clin J Am Soc Nephrol; 2010 Apr; 5(4):582-9. PubMed ID: 20299362
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Niacin in the Treatment of Hyperlipidemias in Light of New Clinical Trials: Has Niacin Lost its Place?
    Zeman M; Vecka M; Perlík F; Hromádka R; Staňková B; Tvrzická E; Žák A
    Med Sci Monit; 2015 Jul; 21():2156-62. PubMed ID: 26210594
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Elevating your HDL game. "Good" cholesterol levels can be increased in several ways, but taking niacin is the most effective.
    Harv Health Lett; 2010 Jul; 35(9):6-7. PubMed ID: 20821856
    [No Abstract]   [Full Text] [Related]  

  • 54. [Drug therapy of hyperlipidemia].
    Kajiyama G; Horiuchi I
    Nihon Rinsho; 1990 Nov; 48(11):2620-8. PubMed ID: 2270030
    [No Abstract]   [Full Text] [Related]  

  • 55. Adverse reactions of Achilles tendon xanthomas in three hypercholesterolemic patients after treatment intensification with niacin and bile acid sequestrants.
    Lakey WC; Greyshock N; Guyton JR
    J Clin Lipidol; 2013; 7(2):178-81. PubMed ID: 23415439
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Consistency of extended-release niacin/laropiprant effects on Lp(a), ApoB, non-HDL-C, Apo A1, and ApoB/ApoA1 ratio across patient subgroups.
    Bays HE; Shah A; Lin J; Sisk CM; Dong Q; Maccubbin D
    Am J Cardiovasc Drugs; 2012 Jun; 12(3):197-206. PubMed ID: 22500948
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A case for immediate-release niacin.
    Bassan M
    Heart Lung; 2012; 41(1):95-8. PubMed ID: 21414665
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Correction of refractory thrombocytopenia and anemia following withdrawal of extended release niacin.
    O'Connell C; Horwood K; Nadamuni M
    Am J Hematol; 2016 Jul; 91(7):E318. PubMed ID: 27012809
    [No Abstract]   [Full Text] [Related]  

  • 59. Effects of high-dose modified-release nicotinic acid on atherosclerosis and vascular function: a randomized, placebo-controlled, magnetic resonance imaging study.
    Lee JM; Robson MD; Yu LM; Shirodaria CC; Cunnington C; Kylintireas I; Digby JE; Bannister T; Handa A; Wiesmann F; Durrington PN; Channon KM; Neubauer S; Choudhury RP
    J Am Coll Cardiol; 2009 Nov; 54(19):1787-94. PubMed ID: 19874992
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Safety considerations with niacin therapy.
    Guyton JR; Bays HE
    Am J Cardiol; 2007 Mar; 99(6A):22C-31C. PubMed ID: 17368274
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.